Binding Affinities of Ocular Hypotensive β-Blockers Levobetaxolol, Levobunolol, and Timolol at Endogenous Guinea Pig β-Adrenoceptors

Journal of Ocular Pharmacology and Therapeutics

Volumn 20, Issue 2, 2004, Pages 93-99

  Sharif, N A ^a   Xu, S X ^a  

^a ALCON RESEARCH LTD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; 4 [2 [(2 HYDROXY 3 PHENOXYPROPYL)AMINO]ETHOXY]PHENOXYACETIC ACID; 4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; LEVOBETAXOLOL; LEVOBUNOLOL; TIMOLOL; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; GUINEA PIG; HEART; IC 50; LUNG; NONHUMAN;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BETAXOLOL; BINDING, COMPETITIVE; GUINEA PIGS; HEART; INTRAOCULAR PRESSURE; LEVOBUNOLOL; LUNG; MYOCARDIUM; RECEPTORS, ADRENERGIC, BETA; TIMOLOL;

EID: 1842579630     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/108076804773710759     Document Type: Article

References (27)

1. Zimmerman, T.J. Topical ophthalmic beta blockers: a comparative review. J. Ocul. Pharmacol. 9:373-384, 1993.
2. 1-adrenoceptor antagonist. Br. J. Pharmacol. 66:445, 1979.
3. 2-adrenoceptors in the bovine trachea and heart. Br. J. Pharmacol. 108:481-489, 1993.
4. 2-adrenoceptor inhibition. Clin. Pharmacol. Ther. 47:578-583, 1990.
5. Osborne, N.N., Cazevielle, C., Carvalho, A.L., Larsen, A.K., and DeSantis, L. In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent. Brain Res. 751:113-123, 1997.
6. Osborne, N.N., DeSantis, L., Bae, J.H., Ugarte, M., Wood, J.P.M., Nash, M.S., and Chidlow, G. Topically applied betaxolol attenuates NMDA-induced toxicity to ganglion cells and the effects of ischaemia to the retina. Exp. Eye Res. 69:331-342, 1999.
7. + channels: comparison with other β-adrenoceptor antagonists. Br. J. Pharmacol. 130:759-766, 2000.
8. Wood, J.P.M., DeSantis, L., Chao, H-M., and Osborne, N.N. Topically applied betaxolol attenuates ischemia-induced effects to the rat retina and stimulates BDNF mRNA. Exp. Eye Res. 72:79-86, 2001.
9. Endo, S., Tomita, H., Ishiguro, S.-I., and Tamai, M. Effect of betaxolol on aspartate aminotransferase activity in hypoxic rat retina in vitro. Jpn. J. Pharmacol. 90:121-124, 2002.
10. 1-adrenoceptor antagonist, protects a transient ischemic injury of the retina. Exp. Eye Res. 75:591-601, 2002.
11. Collier, R.J., Landers, R., Martin, E.A., Agarwal, N., and Kapin, M.A. Betaxolol and its isomers are neuroprotective in a photic retinopathy model. Invest. Ophthalmol. Vis. Sci. 41(suppl):Abst. #974, S187, 2000.
12. Agarwal, N., Martin, E., Krishnamoorthy, R.R., Landers, R., Wen, R., Krueger, S., Kapin, M., and Collier, R.J. Levobetaxolol-induced up-regulation of retinal bFGF and CNTF mRNAs and preservation of retinal function against a photic-induced retinopathy. Exp. Eye Res. 74:445-453, 2002.
13. Sharif, N.A., Xu, S.X., Crider, J.Y., McLaughlin, M., and Davis, T.L. Levobetaxolol (Betaxon™) and other β-adrenergic antagonists: preclinical pharmacology, IOP-lowering activity and sites of action in human eyes. J. Ocul. Pharmacol. Ther. 17:305-317, 2001.
14. Dahlin, D.C., Curtis, M.A., DeSantis, L., and Struble, C.B. Distribution of betaxolol to posterior ocular tissues of the cynomolgus monkey following a 30-day BID topical ocular regimen of Betoptic S. Invest. Ophthalmol. Vis. Sci. 41(suppl 4): Abst. #2710, S509, 2000.
15. Silver, L.H., Von Tress, M., Garadi, R., and McCarty, G. The Levobetaxolol Dose-Response Study Group. A dose-response evaluation of the ocular hypotensive effects of levobetaxolol ophthalmic suspension in patients with open-angle glaucoma or ocular hypertension. Invest. Opthalmol. Vis. Sci. 41(suppl): Abst. #2734, S513, 2000.
16. Kaiser, H.J., Flammer, J., Stumpfig, D., and Hendrickson, P. Long-term visual field follow-up of glaucoma patients treated with beta-blockers. Surv. Ophthalmol. 38:S156-S159, 1994.
17. Evans, D.W., Harris, A., and Cantor, L.B. Primary open-angle glaucoma patients characterized by ocular vasospasm demonstrate a different ocular vascular response to timolol versus betaxolol. J. Ocul. Pharmacol. Ther. 15:479-487, 1999.
18. Vago, T., Bevilavilacqua, M., Dagni, R., Meroni, R., Frigeni, G., Santoli, C., and Norbiato, G. Comparison of rat and human left ventricle beta-adrenergic receptors: subtype heterogeneity delineated by direct radioligand binding. Biochem. Biophys. Res. Comm. 121:346-354, 1984.
19. 2 adrenoceptors in mammalian lung: evidence from direct binding studies. Mol. Pharmacol. 14:996-1005, 1978.
20. 2 adrenoceptors in mouse trachea and lung: a quantitative autoradiographic study. Br. J. Pharmacol. 99:136-144, 1990.
21. 3-adrenergic agonists. Drugs of Future 18:529-549, 1993.
22. Alexander, S.P.H., Mathis, A., and Peters, J.A. TiPS Nomenclature Supplement. Trends Pharmacol. Sci. (suppl.) (Twelfth ed.), 2001.
23. Riemele, T.J., Henry, D.E., Giesa, F.R., Buckley, S.K., Geiger, G., Heaslip, R.J., Lee, D.K.H. and Grimes, D. Comparison of the β-adrenoceptor affinity and selectivity of cetamolol, atenolol, betaxolol and 1CI-118,551. J. Cardiovasc. Pharmacol. 12:208-217, 1988.
24. Louis, S.N.S., Nero T.L., Iakovidis, D., Jackman, G.P., and Louis, W. LK-204-545, a highly selective adrenoceptor antagonist a human β-adrenoceptors. Eur. J. Pharmacol. 367:431-435, 1999.
25. 2-adrenoceptors in immortalized human trabecular meshwork and non-pigmented ciliary epithelial cells. J. Ocul. Pharmacol. Ther. 18:221-230, 2002.
26. Sharif, N.A., Crider, J.Y., Xu, S.X., McLaughlin, M., and Davis, T.L. Levobetaxolol (Betaxon™): in vitro pharmacology, intraocular pressure lowering activity and autoradiographic localization of β-adrenoceptors in human eyes. Proc. West. Pharmacol. 44:65-68, 2001.
27. 3H]-GR65630 binding. Br. J. Pharmacol. 102:919-925, 1991.